A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions For the fiscal year ending December 2024, this drug developer is expected to earn -$5.39 per share, which is a change of 39.8% from the year-ago reported number. Curis ...

LEXINGTON, Mass., July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on July 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 25,000 shares of Curis common stock to a new employee, with a grant date of July 1, 2024 (the "Q3 2024 Inducement Grant"). Th ...

Data update expands AML dataset from 5 to 30 patients LEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences. This update includes data for 25 new patients in the FLT3 mutation (FLT3m) and U2AF1/SF3 ...

LEXINGTON, Mass., May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial 800-836-8184 from the United States or 646-357-8785 from ...

Financial Data and Key Metrics Changes - Curis reported a net loss of $11.9 million or $2.05 per share for Q1 2024, compared to a net loss of $11.6 million or $2.39 per share for the same period in 2023 [43] - Research and development expenses increased to $9.6 million in Q1 2024 from $9.1 million in Q1 2023, primarily due to higher employee-related costs [43] - General and administrative expenses were $4.9 million for Q1 2024, slightly up from $4.8 million in Q1 2023 [19] Business Line Data and Key Metrics Changes - The company is focusing on three key areas: emavusertib as a monotherapy for relapsed/refractory AML, as a doublet therapy for primary CNS lymphoma, and as a triplet therapy in frontline AML [15] - Enrollment has begun for the triplet therapy study, which combines emavusertib with azacitidine and venetoclax [7][18] Market Data and Key Metrics Changes - The company expects to report data for 30 relapsed/refractory AML patients treated with emavusertib, including 25 new patients [4] - The response rate for existing treatments in the splicing factor mutation population is notably low, with a benchmark of 0% response rate for Aza-ven [6] Company Strategy and Development Direction - Curis aims to establish emavusertib as a best-in-class treatment for FLT3 AML and to explore its potential in the splicing factor mutation population, which currently has no approved therapies [17][84] - The company is also looking to develop a companion diagnostic for genetically driven populations, depending on FDA discussions [46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming clinical data and the potential for emavusertib to show significant activity in challenging patient populations [42][84] - The company is preparing for discussions with the FDA regarding the registration path for both FLT3 and splicing factor mutation studies [72][93] Other Important Information - Curis has a solid cash position with $40.7 million in cash, cash equivalents, and investments as of March 31, 2024, which is expected to support operations through 2025 [19] - The company is experiencing strong enrollment rates in its studies, reflecting a significant unmet need in AML [61] Q&A Session Summary Question: Will data for both FLT3 and spliceosome mutants be presented? - Yes, data for both populations will be presented, with a top-line review expected [45] Question: Will there be additional data at the EHA conference? - Yes, additional details will be provided at both conferences compared to the abstract data [27] Question: What is the expected response rate benchmark for FLT3 patients? - The benchmark for FLT3 inhibition is gilteritinib, which has a CR/CRh rate of 21% [40] Question: How will the company approach the development of a companion diagnostic? - The company plans to consider a companion diagnostic for genetically driven populations, depending on FDA guidance [46] Question: What is the enrollment status for BTK-naive patients in the lymphoma study? - The study includes both BTK-naive and BTK-experienced patients to compare outcomes [60]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3505116 (State or Othe ...

LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET. To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 ...

Curis (CRIS) shares rallied 19.5% in the last trading session to close at $16.01. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 37.3% gain over the past four weeks.The stock rallied due to the optimism over the development of the company’s lead candidate, emavusertib, which is being evaluated in mid-stage studies for treating various cancer indications like primary central nervous system lymphoma, acute mye ...

LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares of Curis common stock to a new employee, with a grant date of April 1, 2024 (the "Q2 2024 Inducement Grant"). The Q2 2024 Inducement ...

LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024.  Presentation details are as follows: Format: Company Presentation Date: Monday, April 8, 2024 Time: 12:45 PM ET A live webcast and arc ...